Ovid Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (in thousands, except share and per share data) | December 31,2025 | December 31,2024 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $13,153 | $26,301 |
| Marketable securities | 56,482 | 26,774 |
| Prepaid expenses and other current assets | 4,733 | 2,865 |
| Total current assets | 74,368 | 55,940 |
| Marketable securities - noncurrent | 20,812 | — |
| Long-term equity investments | 41,961 | 20,974 |
| Restricted cash | 1,931 | 1,931 |
| Right-of-use asset, net | 11,610 | 12,797 |
| Property and equipment, net | 252 | 433 |
| Other assets | — | 92 |
| Total assets | $150,934 | $92,167 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,956 | $3,192 |
| Accrued expenses | 4,899 | 5,994 |
| Current portion, lease liability | 1,433 | 1,336 |
| Total current liabilities | 8,288 | 10,522 |
| Long-term liabilities: | ||
| Lease liability | 11,986 | 13,419 |
| Total liabilities | 20,274 | 23,941 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 0 and 1,250 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — |
| Common stock, $0.001 par value; 315,000,000 and 125,000,000 shares authorized; 130,184,353 and 71,009,866 shares issued and outstanding at December 31, 2025 and 2024, respectively | 130 | 71 |
| Additional paid-in-capital | 452,445 | 372,489 |
| Accumulated other comprehensive loss | (202) | (35) |
| Accumulated deficit | (321,713) | (304,299) |
| Total stockholders’ equity | 130,660 | 68,226 |
| Total liabilities and stockholders’ equity | $150,934 | $92,167 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.